Purple Biotech Ltd.

Regulatory Filings • Sep 13, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of September 2021 Commission File Number: 001-37643

PURPLE BIOTECH LTD. (Translation of registrant's name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On September 13, 2021, Purple Biotech Ltd. (the "Company" or the "Registrant") issued a press release, "Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update." A copy of this press release is furnished herewith as Exhibit 99.1.

In addition, the Company is announcing that it has made available an updated Company Presentation on its website. A copy of the updated Company Presentation is attached hereto as Exhibit 99.2 and may be viewed at the Company's website at www.purple-biotech.com.

Exhibits

99.1	Press Release
99.2	Company Presentation

Incorporation by Reference

This Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant's Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333- 230584), the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481) and each of the Registrant's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

September 13, 2021 PURPLE BIOTECH LTD.

By: /s/ Isaac Israel

Isaac Israel Chief Executive Officer

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab

Patient Enrollment in Second Dose Cohort Complete

Study Expanding to Additional Sites in U.S. and Israel

REHOVOT, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided an update on its ongoing Phase 1b/2 clinical trial of CM24, a monoclonal antibody blocking CEACAM1, in combination with nivolumab (Opdivo®), a PD-1 inhibitor, in advanced cancer patients, with expansion cohorts in subjects with non-small cell lung cancer (NSCLC) and in combination with nivolumab and nab-paclitaxel (Abraxane®) in pancreatic cancer.

In a Trials in Progress poster at the ESMO 2021 Congress, which will be held on September 16-21, 2021, Purple Biotech will present an overview and the design of the ongoing Phase 1b/2 study. The poster is titled, "A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer."

Top-line data from the first dose cohort of CM24 10mg/kg included a partial response demonstrated in a patient with refractory advanced pancreatic cancer previously treated with two lines of therapy following two courses of treatment with CM24 in combination with nivolumab 480mg/kg. Additionally, there were no dose-limiting toxicities or serious adverse events observed in any of the three patients enrolled in the first cohort of the study.

"We are encouraged by the early data from the first cohort of this study, which showed combination agent safety, as well as a partial response in one patient," said Bertrand C. Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "The responsive patient showed a 40 percent reduction in tumor size following two courses of treatment with CM24 10mg/kg in combination with nivolumab. In addition, levels of CA19-9 tumor marker dropped by 56%, which was comparable to baseline levels. These results are especially compelling given that pancreatic tumors without high levels of microsatellite instability or deficient mismatch repair, such as the responsive patient, typically do not respond to immuno-oncology agents."

Enrollment in the second dose cohort (15mg/kg) has successfully concluded. Moreover, the Phase 1b/2 study is being expanded to additional sites in the U.S. and Israel.

"The top-line data from the first cohort of this study reinforce our confidence in the potential of CM24 to be a safe and effective treatment for advanced cancer patients. Moreover, we are pleased with the high level of interest in this study from some of the leading academic centers in the world and look forward to completing this dose-escalation study by year-end, as planned," said Isaac Israel, Chief Executive Officer of Purple Biotech.

The study is a Phase 1b/2 clinical trial with expansion cohorts in subjects with NSCLC and pancreatic cancer. CM24 is dose escalated (3+3 design) from 10mg/kg, in combination with nivolumab, 480mg q4w, in Phase 1b, in patients with NSCLC, pancreatic cancer, ovarian carcinoma, colorectal adenocarcinoma, melanoma, or thyroid carcinoma, with the primary objective of evaluating safety, PK and determining the recommended Phase 2 dose. In the Phase 2 component, patients with NSCLC will be treated with CM24 and nivolumab after first-line immuno-oncology failure, and patients with advanced/metastatic pancreatic adenocarcinoma will be treated with CM24, nivolumab, and nab-paclitaxel (Abraxane®) after first-line therapy failure, with study endpoints being safety and preliminary efficacy. CEACAM1 level of expression, as well as a number of other immune, biochemical and adhesion-related molecules, will be evaluated as potential biomarkers in the study.

Additional information about the trial can be found at www.clinicaltrials.gov, NCT Identifier NCT04731467.

The trial is being conducted under a clinical collaboration and supply agreement with Bristol Myers Squibb. Purple Biotech is the sponsor of the trial.

Opdivo® is a trademark of Bristol-Myers Squibb Company.

Abraxane® is a trademark of Abraxis BioScience, LLC, a Bristol Myers Squibb company.

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (Abraxane®) in patients with pancreatic cancer. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://www.purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2020 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

Company Contact:

Gil Efron President & Chief Financial Officer IR@purple-biotech.com

Investor Relations Contact:

Chuck Padala chuck@lifesciadvisors.com +1 646-627-8390

Media Contact:

Megan Humphreys megan@mlhconsulting.com

Exhibit 99.2

Forward-looking Statements and Safe Harbor

Certain statements in this presentation that are tratements of historical fact are forward-looking statements within the meaning of the safe hardor provisions of the Private Securities Litigation Act of 1995. Such forward include, but are not imited to, statements of historical fact, and may be identified by words such as "believ", "expec", "intend", "could", "might", "seek", "will", "project", "forecast", "continue" or their negatives or varialins of these words or other comparable words. You should reliance on these forward to know and sugarantees of tricure performance. For ward-ooking statements reflect our current views, expect to intentions with respect to future events, and are subject to a number of assumptions, inother and unhown risks, nam of which are beyond our control, as well as uncertaining and our actual results, performance or addievenents to be significantly diferent from any futre results, performance or achievenents expressed or inplied by the forward factors that could cause or contribute to such differences induct, anong others, risks relating to the plans, strategies and objectives of nanagement for future operation the NT2.9 and CM24; the process by which early stage therapeutic candidates such as NT29 and CM24 could potentially lead to an approved drup and subject on lighty significant risks, particularly with respect to a joint development and commercialization involves a lengthy and expense; our ability to successfully develop and connecialize our pharmaceuital product; the experse, length, pogress and results of any clinical that of suffical trials; the clinical trials; the impact of any changes in regulation and legistion that could affect the pharnaceuical industry the difficulty in receiving the regulatory in order to commercialize our products; the difficulty of predicing actions of the U.S. Food and Doug Administration or an other applicable regulator of plannaceutial production and changes in the health policis and regimes in the countries in which we operate the uncertainy surrounting the actual market reeption once cleared for narketing in a particular market, the introduction of competing poducts, patents attained by competitors, dependence on the effectivenes of our protections for innovative products; our ability to obtain and defend issued patent of any patent interference or infingenent action of patility to prevall, obtain a favorable decision or recover damages in any such action; and the exposure to liteation, including patent litigation, and other factors that are discussed in our in our Anval Report on Form 20-F for the year ended December 3, 2020 and in our other filings with the U.S. Securities and Exchange ou cautionary discussion of risk and uncertainies under "Risk Pactor" in our Registation Stateners and Annal Reports. These are hat we believe could cause our actually from expected results. Other factors besides those we have lised could also adversely affect us. Ary forward-looking statenent in this presentation it is made. We disclaim any intention or obligsion to publicy update or revise any forward-looling statener, on other infornation contained here information, foure events or otherwise, except as required by applicable law. You are adviced hovever, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.gov.

Business Highlights

CM24 - First-in-class α-CEACAM1 mAb, validating clinical collaboration with Bristol Myers Squibb

NT219 - First-in-class, small molecule, dual inhibitor of IRS 1/2 and STAT3

H2:21 - Two phase 1 study readouts

Strong balance sheet and cash position Purple Biotech (NASDAQ/TASE: PPBT)

ADSs outstanding: 17.5M

\$53M cash as of June 30st, 2021

Cash runway into 2024

ಷ

Advancing Clinical-stage Novel Oncology Therapies

Advancing First-in-Class Oncology Therapies

CM24 - an α-CEACAM1 mAb

CEACAM1* Plays a Key Role in Cancer Biology

02 | IMMUNE CELLS/ 03 | IMMUNO-01 | ADHESION IMMUNE EXCLUSION ONCOLOGY Tsuzuki, 2020 Blumberg, 2015 Horst, 2011 ୍ତି, Oncogene nature "CEACAM1 creates a pro-angiogenic "Immune-checkpoint molecules on "CEACAM1 regulates tumor microenvironment that regulatory T-cells as a potential TIM-3-mediated tolerance and supports tumor vessel maturation" exhaustion" therapeutic target in head and neck squamous cell cancers" Ferri, 2020 Tsang, 2020 Shively, 2013 Cancer Biotherapyas

Radiopharmaccuticals @ immunology Experimental
Cell Research "Neutrophil extracellular trap-"[Blockade] enhances natural "CEACAM1 regulates Fas-mediated associated CEACAM1 as a putative killer cell cytotoxicity against apoptosis in Jurkat T-cells via its therapeutic target to prevent tumor cells through blockade of the interaction with ß-catenin" metastatic progression of colon inhibitory CEACAM1 / CEACAM5 carcinoma" immune checkpoint pathway" *Carcinoembryonic Antigen Cell Adhesion Molecule 7

CM24 MOA | Immuno-oncology

ારાગા

Anti-cancer Effect Following Treatment Preclinical Data With CM24 + TIL and CM24 + α-PD1

mortalities

(RECIST)

11

study drug due to an AE

10 mg/kg

PK/PD Modeling Provides Dosage & Schedule Guidance

• · Consistent with observed PK showing high clearance at doses <10 mg/kg, plot shows low TMDD saturation at low doses
• · 10 mg/kg has a broad range of saturation, and >10 mg/kg, Q2W dose is needed for saturation across population
• · Nivolumab administered Q2W or Q4W, representing good clinical and commercial fit for CM24

JRPL

Simulated TMDD1 saturation at Ctrough

Phase 1b/2a study will continue escalating the CM24 dose above 10mg/kg q2wk, in combination with nivolumab

-Target-meliated drug disposition. ^OPDVO®'s a registed trademark of Bristol-Myers Squibt. Crough is the before the next dose is administered

Large Market Opportunity in NSCLC & Pancreatic Cancer

• NSCLC accounts for ~200K new cases/year in the US; with a 5-year relative survival rate of 23%2
• Immunotherapy is now recommended as first line therapy in all patients with NSCLC and no driver mutations3
• 5-year overall survival rates with chemotherapy in 2L is 2.6% and with I/O Opdivo® is 13.4%ª

Pancreatic Cancer accounts for ~60K new cases/year in the US; with a 5-year relative survival rate of 10%2

• I/O approaches have been limited to patients with high microsatellite instability (MSI-H) or high tumor mutational burden (TMB-H)
• · 5-year overall survival rates with chemotherapy in 2L is 3%2

Combining nivolumab with CM24 in a clinical collaboration with

(III Bristol Myers Squibb"

• · CEACAM1 expression correlates with poor prognosis in NSCLC and Pancreatic cancer1
• · Preclinical data support significant synergy
• · Receptor saturation with CM24 is better achieved with a Q2W regimen, aligning with the nivolumab regimen

1 Dango et al, Lung Cancer 2008; 60:426 & Calinescu et al, Journal of Immunology Research 2018: 7169081. 2 American Concer Society, Concer Frect & Figures 2019, Intros://set.com.cn.gov/stat/ter/ton/porces.t.ml
3 Economopoulou P, Mountzios G. The emerging treament inn-snall cell 4 Getinger S, et al "Five-year outcomes for this CheckMate 01/057: Wolunab is docetaxel in previously treated NCCC" WCLC 2019; Abstract OAL 1.0.

CM24 Phase 1/2 Combination Study Design (NCT04731467)

Measurement of CEACAM1 based A Phase 1/2 open label multi center Primary endpoints: bio-marker. study of CM24 in combination with: Phase 1: Evaluate the safety, PK and the MTD/RP2 dose · Nivolumab in selected cancer indications Exploring further studies in other (Phase 1) and NSCLC (Phase 2) Phase 2: Evaluate preliminary efficacy in tumor types as well as monotherapy 2nd line NSCLC and pancreatic cancer • Nivolumab and nab-paclitaxel in pancreatic cancer (Phase 2) 2021 2022 2023-24 Dose Escalation Expansions Doses: 10, 15, 20mg/kg q2wk CM24 (@RP2 dose) + nivolumab (480mg) q4w I/O refractory NSCLC; 2nd line + nivolumab (480mg q4w)

3+3 design

9 ≤ n ≤ 15

Indications: NSCLC, Pancreatic,

Ovarian, CRC, Melanoma,

Papillary Thyroid Carcinoma

CM24 (@RP2 dose) + nivolumab (480mg) q4w + nab-paclitaxel Locally advanced, unresectable pancreatic cancer; 2nd line n=13+14 (Simon 2 Stage Design)

n=13+14 (Simon 2 Stage Design)

Clinical collaboration with: (III Bristol Myers Squibb"

1st Cohort Analysis – SAFETY and RESPONSE

10mg/kg Dose Level in combination with nivolumab

• The administration of CM24 at 10mg/kg q2wks in combination with nivolumab at 480mg q4wks was well tolerated with no SAEs in patients with refractory PDAC
• · Three patients were enrolled into the first dose cohort, all with PDAC. Two patients progressed after 1.5 and 2 months of treatment
• · The third patient, previously treated with FOLFIRINOX and gemcitabine/nab-paclitaxel, had a germline NF1 VUS, with MSI-S and PDL-1 IHC 2+ and 5% staining
• After initial treatment, the patient had a Partial Response of 40%, with a definite reduction of the para-tracheal adenopathy and liver lesions and 56% reduction in CA19-9 levels

Advancing First-in-Class Oncology Therapies

NT219 - A Small Molecule Dual Inhibitor of IRS 1/2 and STAT3

NT219 - Dual Inhibitor of IRS1/2 & STAT3

IRS1/2

• · Scaffold proteins, mediating mitogenic, metastatic, angiogenic and antiapoptotic signals from IGF1R, IR, IL4R and other oncogenes, overexpressed in multiple tumor types
• · Regulates major survival pathways such as the PI3K/AKT, MEK/ERK and WNT/β-catenin
• · Activated as a feedback response to anti-cancer therapies

NT219

STAT3

• · Well-established transcription factor associated with the tumorigenic phenotype
• · Provides a crucial axis to support cell proliferation and survival
• · Active in tumor JAK/STAT3 and TGF-β resistance mechanisms

അതിന്റെ സ്വാതന്ത്രി 2004-ൽ വിക്ഷേത്രം പ്രത്യേക്കും വികസ്ത്രിക്കുന്നത്. അവലംബം 2006-ൽ വായംഗ്രാമാക്കം നേത്രം.അവാദേശം സ്ഥാനം.
തിരിക്കുന്നു വിന്നു കാലാക്കാല കോവലം സംരക്ഷരത്തിലെ 17

Novel MOA: IRS Degradation By NT219 Blocking IGF1R-AKT Pathway¹

1 Binding to IRS 2) Ser-phosphorylation 3) Degradation IGF1R IGF1R IGF1R IGF1R IRS AND 1 ps) S ps (ps) IRS IRS J SURVIVAL APOPTOSIS Covalent binding to IRS1/2 leads to the Serine phosphorylation prevents IRS1/2 is degraded by the dissociation of IRS1/2 from IGF 1R re-binding of IRS1/2 to the receptor proteasome

URPLE

1Reuveni et al. Cancer Res 2013

NT219 Efficacy as Monotherapy

Animal model Head & Neck Cancer (SCC-9) NSG™, PBMCsinjected1

Drugs α-PD1 Cetuximab (Erbitux®) NT219 20mg/kg NT219 60mg/kg

1 NSG mice were injected SC with SCC-9 cells ,PBMC+(18°10' - 10's per mouse) administered week ,pric treatment.
NT219, c+D1, and cetuximob were administered IV (NT219) and ce relevant data adapted from 2020 Multidisciplinary Head and Neck Cancers Symposium Poster presentation

NT219 + Targeted Therapies Established Efficacy in PDX Models

NSCLC

Exon 19 deletion EGFR and T790M, biopsy of bone marrow metastasis, patient previously progressed on afatinib and osimertinib

R/M SCCHN

metastasis, patient previously progressed on chemoradiation, several chemotherapies, and pembrolizumab

Treatments on days 0, 3 and 10, cetuximob - 1mg/mouse, 3 mice/group; PBMCs (1.4M cells/mouse) were injected on day 621 ** p<0.01, * p<0.02 based on one-way ANOVA with post hoc Tukey's HSD test

First Market Opportunity

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Targeting the unmet medical need

• · 1L Standard of care has shifted from chemotherapy towards immuno-
• oncology + chemotherapy • < 20% of R/M SCCHN patients respond to α-PD1s
• 175k new cases/year are expected by 2024

Interim Analysis - SAFETY and RESPONSE

3 mg/kg Dose Level as a Single Agent

• · NT219 has been found to be well-tolerated with minimal adverse events
• · In a patient with refractory GE junction disease, NT219 administration was associated with a partial response (PR):
  • Complete remission at the largest target lesion and one non-target central mesenteric lymph node
  • ✓ Stable Disease at the other non-target lesion pre-carinal lymph node

	Response Analysis
	Cancer Type	Prior Lines of Therapy	Treatment Duration(Weeks)		Best Response *
	Pancreatic Cancer	3	8		PD
					Target lesion: Absent
NT219 3mg/kg	GE Junction Cancer	4	22	PR	Non target lesion 1: Absent
					Non target lesion 2: Stable
	Breast Cancer	11	8		PD

Business Highlights

CM24 - First-in-class α-CEACAM1 mAb, validating clinical collaboration with Bristol Myers Squibb

NT219 - First-in-class, small molecule, dual inhibitor of IRS 1/2 and STAT3

H2:21 - Two phase 1 study readouts

cash position Purple Biotech (NASDAQ/TASE: PPBT)

ADSs outstanding: 17.5M

Strong balance sheet and

\$53M cash as of June 30st, 2021

Cash runway into 2024

We are committed

to providing cancer patients with first-in-class therapies to OVERCOME tumor drug resistance, ENHANCE treatment response and SLOW tumor progression

Appendix A - CM24

Inhibition of Melanoma Growth Following CM24 and CM24 + TIL Treatment

પરાંગા

CM24 activity is Demonstrated as Single Agent and in Combination with TILS

PHASE 1 PK DATA

Target saturation was not reached with doses up to 10mg/kg

• · Modeling with increased interval between doses demonstrates lower TMDD at 10mg/kg dose
• · With Q3W, 20mg/kg dosing is not sufficient for saturation across population

Appendix B - NT219

Selected Publications

NT219 | Suppresses ß-Catenin activity in CRC Cells and Inhibited CRC Brain Metastasis

Targeted inhibition of IRS2 by NT219 or IRS2-SH RNA, suppresses the increased ß-catenin activity and inhibit LS-513 cell viability. Combination of 5-FU and NT219 significantly inhibited the growth of CRC tumors in brain, using intracranial model and extended mice survival.

PURPLE

AACR Annual Meeting, April 2021, AcCR Virual Special Corpence on Enjogrelics and Medolism, Oct 2020, Ido Wolf, MD, Head of Oncology Division, Tel Avir Sourcal Center

RNA Sequencing | Analysis of Tumors Following Treatment

Reduced expression of IRS1, Ki67, FOXM1 & TGFb is exhibited by pancreatic cancer treated with NT219 alone and in combination with gemcitabine

36

Gemzar

+NT219

NT219 - DEMOGRAPHICS & SAFETY 3 mg/kg Dose Level as a Single Agent

Adverse Event Description	Grade 1 n {#Events}	Grade 2 n {#Events} n {#Events}	Grade 3
Abdominal Pain	1(2)	1(1)
Alanine Aminotransferase Increased	1(1)
Alkaline Phosphatase Increased			1(1)*
Aspartate Aminotransferase Increased	1(1)
Back Pain		1(1)
Belching	2(2)
Cellulitis Left Foot		1(1)
Dyspnea	2(2)
Fatigue	1(1)
Nausea	1(1)	1(1)
Rash Pustular		1(1)
Retching	1(2)
Toxic Encephalopathy			1(1) **

Presented at the ASCO annual meeting June 2021